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Structural analysis of the lymphocyte-specific kinase Lck in
complex with non-selective and Src family selective kinase
inhibitors
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Leticia M Toledo, Huilin Zhao and Kurt A Morgenstern*
Background: The lymphocyte-specific kinase Lck is a member of the Src family
of non-receptor tyrosine kinases. Lck catalyzes the initial phosphorylation of
T-cell receptor components that is necessary for signal transduction and T-cell
activation. On the basis of both biochemical and genetic studies, Lck is
considered an attractive cell-specific target for the design of novel T-cell
immunosuppressants. To date, the lack of detailed structural information on the
mode of inhibitor binding to Lck has limited the discovery of novel Lck inhibitors. 
Results: We report here the high-resolution crystal structures of an activated
Lck kinase domain in complex with three structurally distinct ATP-competitive
inhibitors: AMP-PNP (a non-selective, non-hydrolyzable ATP analog);
staurosporine (a potent but non-selective protein kinase inhibitor); and PP2 
(a potent Src family selective protein tyrosine kinase inhibitor). Comparison of
these structures reveals subtle but important structural changes at the
ATP-binding site. Furthermore, PP2 is found to access a deep, hydrophobic
pocket near the ATP-binding cleft of the enzyme; this binding pocket is not
occupied by either AMP-PNP or staurosporine. 
Conclusions: The potency of staurosporine against Lck derives in part from an
induced movement of the glycine-rich loop of the enzyme upon binding of this
ligand, which maximizes the van der Waals interactions present in the complex. In
contrast, PP2 binds tightly and selectively to Lck and other Src family kinases by
making additional contacts in a deep, hydrophobic pocket adjacent to the
ATP-binding site; the amino acid composition of this pocket is unique to Src family
kinases. The structures of these Lck complexes offer useful structural insights as
they demonstrate that kinase selectivity can be achieved with small-molecule
inhibitors that exploit subtle topological differences among protein kinases. 
Introduction
T-cell activation is a complex process that results from the
integrated activation of multiple signal transduction path-
ways [1–3]. One of the earliest T-cell signaling events
observed upon interaction of the T-cell receptor (TCR)
with its ligand, is the CD4/CD8-dependent activation of
lymphocyte-specific kinase (Lck), a member of the non-
receptor Src family of tyrosine kinases [4–8]. Lck phospho-
rylates and activates a number of substrates necessary for
TCR signaling [9]. Perhaps the best understood activity of
Lck is the phosphorylation of immunoreceptor tyrosine-
based activation motifs (ITAMs) in the TCR ζ subunit
[4,6,9]. The extent of ζ chain ITAM phosphorylation dic-
tates the threshold for ligand-mediated TCR signaling and
T-cell activation [10,11]. Phosphorylated ITAMs serve as
high-affinity docking sites for the recruitment of additional
signaling factors, in particular the Syk family tyrosine
kinase ZAP-70 [12,13]. The dual phosphorylation of 
tyrosine residues in the ITAMs by Lck is required for the
binding of tandem ZAP-70 Src homology 2 (SH2) domains
[14–16]. Colocalization of ZAP-70 and Lck to the TCR
ζ-subunit–CD4/8 complex facilitates the Lck-mediated
activation of ZAP-70 and subsequent ZAP-70 autophos-
phorylation [17–21]. Activated Lck and ZAP-70 perpetu-
ate the TCR signaling cascade by providing additional
docking sites for other kinases that contain SH2 domains
(including Fyn, Syk and Itk), adaptor proteins (including
SLP-76, SHC, LAT, FyB and Grap), and transducing ele-
ments (including PLCγ, PI3-kinase and Rac/Rho) [2,3,22].
Biochemical information is then transmitted down multi-
ple signaling pathways, including the Ras/mitogen-acti-
vated protein kinase pathway, the phosphatidylinositol
pathway, and the Rho/Rac pathway [2]. Among other
effects, TCR signaling up-regulates the transcription and
translation of interleukin-2 (IL-2) and IL-2 receptors,
which are prerequisites for T-cell proliferation. 
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Genetic studies have demonstrated that Lck expression is
restricted to lymphocytes. Loss of Lck expression in human
Jurkat T cells results in a loss of signaling in response to
TCR ligation [23,24]. In addition, inactivation of the lck
gene, or expression of dominant negative transgenes in
mice, results in early arrest of thymocyte maturation
[25–27]. These and other biochemical studies have impli-
cated Lck as an essential early mediator of the TCR signal-
ing pathway. Lck therefore represents an attractive target
for therapeutic intervention in T-cell-mediated disorders,
such as autoimmune diseases and transplant rejection. 
Lck is a modular protein consisting of a C-terminal catalytic
domain, a single SH2 and SH3 domain, and a unique N-ter-
minal region. The N-terminal region is involved in anchor-
ing Lck to CD4/8 through Zn2+ coordination with conserved
cysteine residues present in both proteins [28,29]. The
activity of Lck is regulated by the autophosphorylation of
Tyr394 located in the catalytic domain activation loop [30]
and by the phosphorylation of Tyr505 by C-terminal Src
kinase (CSK) [31–33]. Further understanding of the regula-
tion of Lck has been provided by the crystal structures of
two other Src family protein kinases, c-Src and Hck [34–36].
From these structures it can be inferred that the SH2 and
SH3 domains function in part to negatively regulate Lck
activity by forming intramolecular contacts that stabilize the
catalytic domain in an inactive conformation [37]. The SH2
domain binds to phosphorylated Tyr505 and the SH3
domain associates with a proline-containing motif in a hinge
region connecting the SH2 and catalytic domains [34–36].
Release of these intramolecular regulatory constraints by
the dephosphorylation of Tyr505 [38] and/or the presence
of competing SH3/SH2 ligands [39] results in the autophos-
phorylation of Tyr394 in the activation loop and a catalyti-
cally active kinase [19]. A structural basis for Lck activation
has been previously elucidated from the crystal structure of
an autophosphorylated Lck catalytic domain [40].
Protein kinases have been implicated as potential targets for
a variety of clinical applications. Efforts to understand the
molecular constraints necessary to achieve inhibitor potency
and selectivity have been aided by the availability of an
increasing number of crystal structures of different protein
kinases in complex with ATP-competitive inhibitors. One
such inhibitor is staurosporine, an alkaloid that has been
previously shown to inhibit a broad range of tyrosine and
serine/threonine kinases with nanomolar potency [41].
Crystal structures of staurosporine bound to the serine/thre-
onine kinases protein kinase A (PKA) and  cyclin-depen-
dent kinase 2 (CDK2) elucidated the binding mode of this
inhibitor [42,43] (reviewed in [44]). A similar binding mode
has been reported in a recently solved structure of the tyro-
sine kinase CSK in complex with staurosporine [45]. We
present here crystal structures of Lck in complex with stau-
rosporine obtained from both soaking and cocrystallization
experiments. Comparison of these two complexes and those
previously reported further establishes the structural basis
for the high potency and poor selectivity of this inhibitor.
The role of Src family members Lck and Fyn in TCR acti-
vation has been studied with two related Src kinase
inhibitors, PP1 and PP2 [46]. PP1 and PP2 are claimed to
selectively inhibit Lck and c-Src in vitro at concentrations
much lower than those required to inhibit ZAP-70, Janus
kinase 2 (JAK2), epidermal growth factor receptor (EGFR)
kinase and PKA [46]. These compounds also inhibit anti-
CD3-induced protein tyrosine phosphorylation and subse-
quent IL-2 gene activation in T lymphocytes [46]. Thus, it
appears that PP1 and PP2 dissect a component of TCR sig-
naling not distinguished by other immunosuppressive
drugs, such as cyclosporin and FK-506. We present here the
structural basis for the potency and selectivity of these com-
pounds with the crystal structure of PP2 bound to Lck. The
structure will be a useful tool in the design of specific Lck
inhibitors and should allow for the tailoring of the pharma-
cokinetic properties of inhibitors such as PP1 and PP2. 
Results and discussion
AMP-PNP binding to the Lck catalytic domain
To provide a structural basis for understanding the interac-
tions of ATP-competitive inhibitors with Lck, the Lck cat-
alytic domain was cocrystallized with the non-hydrolyzable
ATP analog adenyl imidodiphosphate (AMP-PNP). Consis-
tent with structures of other protein kinases in complex
with ATP analogs [47–49], AMP-PNP binds in the cleft
between the N- and C-terminal lobes of Lck, with a pair of
conserved hydrogen bonds formed between the adenine
base and the backbone of the kinase linker region
(Figures 1a and 2a). The γ-phosphate of AMP-PNP is disor-
dered in the binary complex, perhaps due to the absence of
a substrate peptide or divalent cations. In the ternary com-
plexes of PKA with bound ATP and a substrate peptide
inhibitor [47,48] and insulin receptor tyrosine kinase (IRK)
with AMP-PNP and a substrate peptide [49], the bound
peptides appear to help anchor the γ-phosphate of ATP to
the enzyme. Only small conformational changes are
observed in the Lck–AMP-PNP complex relative to the
previously reported apo Lck structure [40]. However,
Ser323 undergoes a conformational change in the ribose-
binding pocket of Lck that appears to be important for
AMP-PNP binding. In the apo Lck structure, Ser323
adopts two partially occupied conformations: one conforma-
tion results in a hydrogen bond between Ser323 and Asp326
and the other results in Ser323 hydrogen bonding to the
backbone carbonyl of Asp368. In both conformations, the
Ser323 Oγ points away from the ATP-binding cleft and
faces the C-terminal lobe. In the Lck–AMP-PNP structure,
the sidechain of Ser323 is rotated more than 100° about χ1
and forms a hydrogen bond with the ribose oxygen of AMP-
PNP (Oγ–O2′ distance 2.7 Å). Ser323 of Lck is conserved
among all known Src family tyrosine kinases with the
exception of Blk, which contains a cysteine at this position.
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Staurosporine binding to Lck
Structures of staurosporine bound to Lck were determined
both from apo Lck crystals soaked with inhibitor and from
cocrystals derived from a preformed Lck–staurosporine
complex (Figures 3a and b). Cocrystallization of this
Lck–staurosporine complex produced a new crystal form,
which contains different crystal-packing interactions than
observed in the apo crystal form. In both Lck–stau-
rosporine complexes the inhibitor occupies the
ATP-binding site and forms three hydrogen bonds with
the enzyme. The NH and keto oxygen of the lactam ring
of staurosporine make a pair of hydrogen bonds with the
carbonyl oxygen of Glu317 and the backbone NH of
Met319, similar to those formed by the adenine ring of
ATP (Figures 1b and 2b). The third hydrogen bond,
which occurs in the ribose-binding pocket of Lck, appears
to be different in the two complexes. In the Lck–stau-
rosporine complex derived from soaking, the methylamino
nitrogen of the glycosidic ring participates in a hydrogen
bond with Ser323 (N–Oγ distance 2.9 Å). This interaction
is similar to the hydrogen bond observed between Ser323
and the ribose 2′-hydroxyl group in the Lck–AMP-PNP
complex. In contrast, the methylamino nitrogen of stau-
rosporine in the cocrystallized complex forms a hydrogen
bond with the carbonyl oxygen of Ala368 from the catalytic
loop of Lck (N–O distance 3.2 Å). Although the Ser323 Oγ
is within hydrogen-bonding distance of the methylamino
nitrogen of staurosporine in this complex as well (2.7 Å),
the geometry is not optimal for a hydrogen bond.
Staurosporine also makes extensive van der Waals contacts
with Lck. Seven residues from the N-terminal lobe
(Leu251, Gly252, Val259, Ala271, Lys273, Thr316 and
Tyr318) and six residues from the C-terminal lobe (Met319,
Gly322, Ser323, Ala368, Leu371 and Asp382) of Lck 
contribute a total of 78 van der Waals contacts to the bound
inhibitor (Figure 3a). The majority of these contacts are to
the fused carbazole moiety of staurosporine, which spans a
plane of approximately 15 × 11 Å2. In contrast, the glyco-
sidic group of staurosporine spans only 6 Å  in a direction
perpendicular to the plane of the carbazole ring system.
Approximately half of the van der Waals interactions result
from a large movement of the glycine-rich loop of Lck,
which is induced by staurosporine binding. This movement
is most prominent for the β1 strand of the glycine-rich loop
and is best described as a rotation of this loop about the β2
strand coupled with a small translation towards the C-termi-
nal domain (Figure 4a). The backbone of strand β1 moves
towards the bound ligand by approximately 1.7 Å in the
soaked Lck–staurosporine complex. In the cocrystallized
Lck–staurosporine complex, movement of β1 is even more
pronounced bringing this strand 2.4 Å nearer to the C-ter-
minal lobe. In contrast to the apo crystals used for soaking
experiments, cocrystals of the Lck–staurosporine complex
do not contain lattice contacts in the glycine-rich loop. This
is likely to explain the relative difference in  the position of
this loop in the Lck–staurosporine structures. These two
structures may well represent snapshots of the association
between Lck and staurosporine in solution.
Superimposition of the two Lck–staurosporine complexes
using the C-terminal domain results in a root mean square
(rms) deviation of 0.28 Å between 172 common Cα atoms.
Comparison of the superimposed structures shows that the
largest positional differences occur in the highly flexible
glycine-rich loop of the enzyme (Figure 4a). Interestingly,
although the bound staurosporine molecules superimpose
well in the two structures, the plane of the carbazole moiety
is rotated slightly towards the N-terminal lobe of Lck in the
complex derived from soaking. The net result of this 
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Figure 1
Electron-density maps of ligands bound to Lck. The 2Fo–Fc electron-
density maps are contoured at 1σ. The linker region between the N-
and C-terminal lobes of the Lck kinase domain is shown to the left of
the bound ligands: (a) AMP-PNP; (b) staurosporine; (c) PP2.
Hydrogen bonds formed between the ligands and the kinase linker
region are represented by magenta dashed lines. Atoms are colored by
type: carbon, green; oxygen, red; nitrogen, blue; sulfur, yellow. 
rotation is a 0.8 Å shift of the glycon moiety of staurosporine
towards the glycine-rich loop of the N-terminal lobe. Exam-
ination of the two enzyme–inhibitor structures provides a
ready explanation for this shift. The closest contact between
staurosporine and the glycine-rich loop in the two structures
is a CH–O interaction between the glycosidic oxygen of
staurosporine and the Cα atom of Gly252. This CH–O dis-
tance is 3.5 Å in the cocrystallized complex and 3.6 Å in the
complex derived from soaking. Because the glycine-rich
loop has not rotated as far towards the C-terminal domain in
the soaked Lck–staurosporine complex, the bound ligand
must rotate slightly in order to maintain this interaction. As
a result of this rotation, the glycon methylamino group of
staurosporine is shifted away from the carbonyl oxygen of
Ala368 in this complex, resulting in an NH–O distance of
4.1 Å as compared to 3.2 Å in the cocrystallized complex.
Crystal structures of the protein kinases CDK2, PKA and
CSK in complex with staurosporine have also been
reported [42,43,45]. The same hydrogen-bonding pattern
observed between the lactam ring of staurosporine and the
linker region of Lck is observed in each of these crystal
structures. Inspection of the PKA–staurosporine and
CDK2–staurosporine complexes (CSK coordinates not
available) reveals that the CH–O interaction described
above for the two Lck–staurosporine structures is present
as the closest contact between staurosporine and the
glycine-rich loop in these structures as well. Not only are
the CH–O distances constant in the four complexes
(3.5 Å), but the geometry of the interaction is similar. This
type of CH–O interaction is well documented in small-
molecule crystal structures [50] and has also been observed
in other biomolecular complexes [51]. Interestingly, both
PKA and CDK2 undergo conformational changes in the
glycine-rich loop upon staurosporine binding and,
although this loop contains additional conformational dif-
ferences in the CDK2 complex (Figure 4b), the interaction
between the glycine Cα atom and the glycosidic oxygen is
maintained. This emphasizes the importance of this inter-
action in complexes between staurosporine and
serine/threonine and tyrosine kinases. We propose that
this interaction is critical for the potency of staurosporine
binding to the ATP-binding site of these kinases. 
In both the Lck and CSK complexes a single hydrogen
bond is formed between staurosporine and the ribose-
binding pocket [45]. In comparison, staurosporine has
been observed to form two hydrogen bonds with this
pocket in CDK2 and PKA [42,43]. In these two complexes
rotation about the C–N bond of the methylamino sub-
stituent allows the amine nitrogen to hydrogen bond to
both a carbonyl oxygen from the catalytic loop and a
sidechain from the ribose-binding pocket. Of the two
methylamino hydrogen-bonding interactions observed in
our Lck–staurosporine complexes, the contact with the
carbonyl oxygen of Ala368 most closely resembles the
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Figure 2
Schematic representation of the hydrogen-bond interactions and van
der Waals contacts between Lck and bound ligands: (a) AMP-PNP;
(b) staurosporine; (c) PP2. Hydrogen bonds are represented with
dashed lines. The residues of Lck in contact with the bound ligand
are shown. 
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Structure
interactions observed in the PKA and CDK2 complexes.
The distance between this carbonyl oxygen and the Cα
atom of Gly252 is 10.3 Å and 9.6 Å, respectively, for the
soaked and cocrystallized Lck–staurosporine complexes.
The equivalent distances in the PKA and CDK2 struc-
tures are 9.0 Å and 8.8 Å, respectively. This indicates that
the Lck–staurosporine cocrystal structure is more likely to
represent a physiologically relevant structure, with a
slightly more open conformation than those of PKA and
CDK2 in complex with staurosporine.
PP2 binding to Lck
PP2 has been reported to be a potent Src family selective
tyrosine kinase inhibitor [46]. This compound inhibits Lck
with an IC50 of 4 nM and Fyn with an IC50 of 5 nM. PP2 is
slightly less potent against EGFR (IC50 = 0.45 µM) and
inactive against ZAP-70 (IC50 = 100 µM) [46]. PP1, an
analog of PP2, shows approximately the same inhibitory
activity against Lck [46]. To determine the structural basis
for this selectivity, PP2 was cocrystallized with the kinase
domain of Lck. The structure of this complex reveals that
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Figure 3
Interactions of (a,b) staurosporine and
(c,d) PP2 with Lck at the ATP-binding cleft.
The residues of Lck in contact with the bound
ligand are shown in yellow in (a) and (c). Parts
(b) and (d) show the surface curvature of Lck
when bound to staurosporine and PP2,
respectively. The most convex parts of the
molecular surface are colored green, the most
concave regions gray and the most planar
parts are in white. 
Figure 4
Structural comparison of protein kinases bound
to staurosporine. (a) Superposition of the
structures of apo Lck (orange), the
Lck–staurosporine complex derived from the
soaking experiment (green) and the
Lck–staurosporine complex obtained from
cocrystallization (purple). The superposition is
based on the kinase domain of Lck. The ligand
from the soaking experiment is shown in cyan
and staurosporine from the cocrystallization
experiment is shown in purple.
(b) Superposition of Lck (green), CDK2 (cyan)
and PKA (yellow) in complex with staurosporine
(purple). The structure alignment is based on
the bound ligands. The Lck–staurosporine
cocrystallization complex contains a loop
conformation that is intermediate between the
more open and closed positions observed in
the CDK2 and PKA complexes.
PP2 binds in the ATP-binding site and induces little
global conformational change in the enzyme. Superimposi-
tion of the Lck–PP2 and Lck–AMP-PNP structures yields
an overall rms difference of 0.27 Å for 278 Cα atoms. The
pyrazolopyrimidine ring of PP2 occupies a similar position
in the Lck ATP-binding cleft as the adenine ring of AMP-
PNP (Figures 1c and 2c). This binding mode places the 3-
(4-chlorophenyl) substituent of PP2 in a hydrophobic
pocket adjacent to the ATP-binding cleft (Figures 3c and
3d). PP2 forms three hydrogen bonds with Lck, two of
which are similar to those found in the Lck–AMP-PNP
and Lck–staurosporine structures (Figures 1c and 2c).
These hydrogen bonds are between the 4-amino group of
PP2 and the backbone carbonyl of Glu317, and between
the N5 of PP2 and the backbone NH of Met319. The
third hydrogen bond, formed between the 4-amino group
of PP2 and the sidechain hydroxyl group of Thr316, is
unique in the structures reported here. The two conserved
hydrogen bonds in the Lck–PP2 complex are relatively
long, with distances between donor and acceptor atoms of
approximately 3.2 Å. PP2 also makes 38 van der Waals
interactions with Lck. Of these contacts, 19 involve the 3-
(4-chlorophenyl) substituent, which is deeply buried
inside the hydrophobic pocket. The tert-butyl substituent
of the pyrazolopyrimidine contributes four van der Waals
contacts to the complex. This substituent is located at the
entrance of the ATP-binding pocket and contacts residues
from both the N- and C-terminal lobes of Lck.
The hydrophobic pocket occupied by the 3-(4-
chlorophenyl) substituent of PP2 is defined by residues
Thr316, Ile314, Met292, Glu288 and Lys273. The exact
composition of this pocket appears to be unique to the Src
family (Figure 5). For instance, Thr316, which is located at
the entrance of the hydrophobic pocket, is not conserved
in other tyrosine kinase families. ZAP-70 contains a
methionine at this position, which is likely to block access
of this pocket to PP2-like inhibitors. This observation is
consistent with the 100 µM IC50 previously reported for
PP2 against ZAP-70 [46]. Like Lck, the EGFR kinase has
a threonine at the entrance of the hydrophobic pocket and
is inhibited moderately by PP2 (IC50 = 0.45 µM) [46]. The
hydrophobic pocket in EGFR differs from the Src kinases
by having a leucine at the position equivalent to Ile314 in
Lck. In the Lck–PP2 complex, Ile314 contacts the 4-chloro
substituent of the 3-phenyl ring. The presence of a leucine
at this position in EGFR could partially account for the
weaker inhibition of this receptor tyrosine kinase by PP2. 
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Figure 5
Structure-based sequence alignment of Lck,
ZAP-70, EGFR and PKA. Conserved residues
are highlighted in yellow. The amino acids in the
hydrophobic pocket where PP2 binds are
highlighted in cyan; Tyr394 on the activation
loop is highlighted in magenta. The linker and
catalytic regions are labeled. The positions of
secondary structure elements are indicated with
arrows (β strands) and rectangles (α helices). 
β1 β2 β3
Lck   225       -QTQKPQKPWWEDEWEVPRETLKLVERLGAGQFGEVWMGYY-----NGHTKVAVKSLKQG
ZAP-70          -YSDPEE-LKDKKLFLKRDNLLIADIELGCGNFGSVRQGVYRMRK--KQIDVAIKVLKQG
EGFR            -LTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREA
PKA             AKEDFLKKWESPAQNTAHLDQFERIKTLGTGSFGRVMLVKHKETG----NHYAMKILDKQK
αC β4 β5 linker αD
Lck   279       SMS---PDAFLAEANLMKQLQHQRLVRLYAVVTQEPIYIITEYMENGSLVDFLKTPSGIK
ZAP-70          TEKAD-TEEMMREAQIMHQLDNPYIVRLIGVCQAEALMLVMEMAGGGPLHKFLVGKR-EE
EGFR            TSPKA-NKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHK-DN
PKA             VVKLKQIEHTLNEKRILQAVNFPFLVKLEFSFKDNSNLYMVMEYVPG-GEMFSHLRRIGR
αE catalytic β6 β8
Lck   335       LTINKLLDMAAQIAEGMAFIEERNYIHRDLRAANILVSDTLSCKIADFGLARLI--EDNE
ZAP-70          IPVSNVAELLHQVSMGMKYLEEKNFVHRDLAARNVLLVNRHYAKISDFGLSKALGADDSY
EGFR            IGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKE
PKA             FSEPHARFYAAQIVLTFEYLHSLDLIYRDLKPENLLIDQQGYIQVTDFGFAKRV--KGRT
αEF αF αG
Lck   394       YTAREGAKFPIKWTAPEAINYGTFT-IKSDVWSFGILLTEIVTHGRI-PYPGMTNPEVIQ
ZAP-70          YTARSAGKWPLKWYAPECINFRKFS-SRSDVWSYGVTMWEALSYGQK-PYKKMKGPEVMA
EGFR            YHAE-GGKVPIKWMALESILHRIYT-HQSDVWSYGVTVWELMTFGSK-PYDGIPASEISS
PKA             WTLC----GTPEYLAPEIILSKGYNK-AVDWWALGVLIYEMAAGYPP--FFADQPIQIYE
αH αI
Lck   451       NLERG--YRMVRPDNCPEELYQLMRLCWKER—PEDRPTFDYLRSVLEDFFT---------
ZAP-70          FIEQG--KRMECPPECPPELYALMSDCWIYK—WEDRPDFLTVEQRMRACYY---------
EGFR            ILEKG--ERLPQPPICTIDVYMIMVKCWMID—ADSRPKFRELIIEFSKMARDPQR---YL
PKA             KIVSG---KVRFPSHFSSDLKDLLRNLLQVD-LTKRFGNLKNGVNDIKNHKWFATTD-WI
Lck   500       ATEG--QYQ-PQP-----------------------------------------------
ZAP-70          SLAS--KVEGP-PGSTQKAEAACA------------------------------------
EGFR            VIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLS
PKA             AIYQR-KVEAPFIPKFKGPGDTSNFDDYEEEEIRVSINEKCGKEFSEF------------
Structure
The structure of the Lck–PP2 complex helps to explain
the structure activity relationships of a series of 4-amino-
1,3-diphenyl-pyrrolo[3,4d]pyrimidines that show a high
degree of specificity towards c-Src [52]. The molecular
structures of these compounds are analogous to PP2, but
have a phenyl ring at the N1 position of the pyrrole
instead of a tert-butyl group (Figure 6). A wide variety of
polar moieties are well tolerated on this phenyl ring. The
amino acid identity of the active sites of Lck and Src
(defined as a 10 Å radius around ATP) is 89%. The
amino acid composition of the ribose binding pocket
within the Src family is completely conserved, whereas
the hydrophobic pocket is less conserved. Superimposi-
tion of several of these compounds on the Lck–PP2
complex indicates that the polar groups at the N1-phenyl
ring of pyrrolopyrimidines can interact favorably with
hydrophilic residues in the ribose-binding pocket
(Ser343 and Asp345), while the 3-phenyl group occupies
the same region of the hydrophobic pocket as the 3-(4-
chlorophenyl) group of PP2.
Comparison of ligand binding to Lck
Superimposition of the Lck–AMP-PNP, Lck–stauro-
sporine and Lck–PP2 structures highlights similar features
of inhibitor binding to the enzyme. The aromatic ring
systems of the bound inhibitors occupy similar positions in
the adenine-binding pocket, as do their hydrogen-bond
donors and acceptors (Figure 7). This results in a hydro-
gen-bonding pattern to the backbone carbonyl of Glu317
and the amide of Met319 that is conserved in all three
structures (Figures 1 and 2). 
Staurosporine makes significantly more interactions with
the glycine-rich loop of Lck than does either AMP-PNP or
PP2. The majority of these interactions are with residues
that are highly conserved among protein kinases. These
include Leu251, Gly252, Val259, Ala271, Lys273, Gly322
and Leu371, residues that are either absolutely or highly
conserved among known tyrosine kinase sequences. In
contrast, PP2 makes a number of interactions with
residues that are specific to the Src family kinases by
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Figure 6
The chemical structures of PP1, PP2 and 
4-amino-1,3-diphenyl-pyrrolo[3,4-d]pyrimidines.
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Structure
Figure 7
Comparison of the ligand positions in the Lck
complexes based on a superposition of the
Cα atoms of Lck. (a) AMP-PNP (purple) and
staurosporine (white). (b) AMP-PNP (purple)
and PP2 (white).
accessing a hydrophobic pocket neighboring the adenine-
binding region of Lck. This hydrophobic pocket exists in
other kinases as well and has been exploited in the discov-
ery of specific inhibitors. For example, structures of
fibroblast growth factor receptor (FGFR) and p38
mitogen-activated protein (MAP) kinases bound with spe-
cific inhibitors show that the inhibitors gain both potency
and specificity by placing substituents in this hydrophobic
pocket [53–56]. However, the exact position and topology
of the hydrophobic pockets of Lck, FGFR, p38 and other
kinases are likely to be defined not only by sequence, but
by additional factors such as activation state or relative
positioning of the kinase N- and C-terminal domains. This
diversity around the ATP-binding site provides opportuni-
ties for the discovery or design of potent, selective, small-
molecule inhibitors for specific protein kinases.
Inhibition of Lck activity and T-cell receptor signaling
In the crystallographic studies presented here, the catalytic
domain of Lck was used as a substitute for the full-length
protein. Previous studies have demonstrated that the Lck
catalytic domain can be expressed and isolated as a consti-
tutively active enzyme [40]. Nevertheless, a detailed com-
parison of the catalytic activities of Lck in the full-length
and truncated forms has not been reported. To provide a
basis for the physiological relevance of our crystallographic
studies, the IC50 values of staurosporine and PP2 were
measured against these two forms of Lck. The full-length
and catalytic domains of Lck displayed comparable specific
activities (10 and 15 nmoles/min/nM enzyme, respectively)
when assayed using a poly-Glu-Tyr substrate. Further-
more, staurosporine (IC50 full-length = 34 nM, kinase
domain = 40 nM) and PP2 (IC50 full-length = 19 nM,
kinase domain = 20 nM) each inhibited both the full-
length and truncated forms of Lck to a similar extent in an
autophosphorylation assay (Figure 8a). 
The effect of staurosporine and PP2 on the Lck-medi-
ated phosphorylation of TCR ζ chain and IL-2 produc-
tion in human T cells was also investigated. Both
inhibitors showed a dose-dependent inhibition of Lck-
dependent phosphorylation of the TCR ζ chain (p23),
and also inhibited the phosphorylation of a 70 kDa
protein which is likely to be ZAP-70 (Figure 8b).
Figure 8c, shows that staurosporine (IC50 = 60 nM) and
PP2 (IC50 = 600 nM) also exhibited dose-dependent inhi-
bition of IL-2 production in human T-cell cultures. The
results of these in vitro and cellular studies suggest that
the catalytic domain of Lck is a valid substitute for the
full-length Lck as a molecular target for the development
of new immunosuppressive therapeutic agents. 
Biological implications
The molecular targets of currently used immunosup-
pressive drugs such as FK-506 and cyclosporine are
broadly expressed in many different tissues and cell
types. The non-immunosuppressant toxicity profiles of
such drugs can be traced to the inhibition of their targets
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Figure 8
Inhibition of Lck activity. (a) Enzymatic assay. IC50 titration curves for
the Lck catalytic domain (squares) and the nearly full-length enzyme
with SH2 and SH3 regulatory domains (circles). The Lck proteins were
titrated with staurosporine (open symbols) and PP2 (filled symbols).
(b) Endogenous protein phosphorylation assay. PP2 and staurosporine
inhibit TCR-induced increases in phosphotyrosine incorporation into
the TCR ζ chain (p23) and a 70 kDa protein (see Materials and
methods section for details). (c) Cellular assay. PP2 (filled diamonds)
and staurosporine (filled triangles) inhibit TCR-induced IL-2 secretion
from human peripheral blood lymphocytes. 
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in non-lymphoid tissues. Targeting lymphocyte-specific
kinase (Lck) for the development of novel immunosup-
pressive drugs has promise, as this enzyme is selectively
expressed in T cells and natural killer (NK) cells. Thus,
agents that selectively inhibit Lck could lead to T-cell-
specific immunosuppression with improved therapeutic
windows and broader clinical potential. 
In the past few years much progress has been made in
the design of selective kinase inhibitors. It has been estab-
lished that highly specific ATP-competitive inhibitors can
be obtained against a number of different kinases with
clinical utility in oncology. In the present study, a com-
parison of several ligated Lck structures has provided
valuable insight into the mode of binding of non-selective
and Src family selective inhibitors. The structure of Lck
in complex with a non-hydrolyzable analog of ATP,
AMP-PNP, is likely to represent a conformation of Lck
when ATP is bound prior to the binding of substrates and
phosphotransfer. Analysis of the Lck–staurosporine
complex reveals that binding of this inhibitor to Lck and
other kinases induces a conformational change in the
glycine-rich loop, which helps to  maximize van der
Waals interactions. This conformational change is medi-
ated by a CH–O interaction that appears to be a common
component of kinase–staurosporine complexes. The non-
selectivity of staurosporine may be explained by interac-
tions with residues that are highly conserved in the
ATP-binding cleft. In contrast, the Src-selective inhibitor
PP2 binds to Lck by accessing a hydrophobic pocket, the
composition of which is unique to the Src family. The
structures of these Lck complexes offer useful structural
insights as they demonstrate binding modes that make dif-
ferential use of various regions of the ATP-binding cleft.
Furthermore, these complexes indicate that kinase selec-
tivity can be achieved with small-molecule inhibitors that
exploit subtle topological differences or sequence substitu-
tions among protein kinases. 
Materials and methods
Construct design, protein expression and protein purification
Full-length Lck cDNA (a gift from T Roberts, DFCI) was used as a tem-
plate for the amplification of a 879 base pair fragment encoding amino
acid residues 225–509 of the Lck catalytic domain using the poly-
merase chain reaction (PCR). The PCR product was cloned into the
Bam HI and Eco RI sites of the plasmid vector pFastBac1(Gibco/BRL)
modified to contain the coding region for glutathione-S-transferase
(GST) and a thrombin cleavage site upstream of the multiple cloning
site. Recombinant baculovirus was obtained using the Bac-to-Bac
expression system (Gibco/BRL). After two rounds of amplification in
Sf9 insect cells (Spodoptera frugiperda) cultured in Hink’s modification
of Graces media, the virus was used to infect High Five insect cells
(Trichoplusia ni) grown in Ex-cell 405 media for protein production. 
Recombinant GST–Lck residues (225–509) was purified from bac-
culovirus cells essentially as previously described [40], except that the
first step involved fractionating cell lysates on glutathione sepharose
(Pharmacia Biotech). The GST–Lck bound to the resin was eluted with
30 mM glutathione and cleaved overnight at 4°C with the fusion protein
at 0.5 mg/ml and α-thrombin added at a 1:1000 ratio (w/w). A pro-
tease inhibitor cocktail was then added and the protein sample was
incubated for 30 min at 25°C. The inhibition of thrombin was confirmed
in a spectrophotometric assay as described [57,58]. The cleaved GST
and Lck were separated by anion exchange chromatography essentially
as described for the separation of Lck phosphorylation species [40].
The pooled fraction of Lck was then concentrated in a centriprep-10
and size fractionated on a column of superdex-75. The monomeric frac-
tion appeared homogeneous by sodium dodecyl sulfate (SDS) and
native polyacrylamide gel electrophoresis (PAGE). 
Structure determination
Crystals of the Lck kinase domain in complex with AMP-PNP/Mg
(5 mM) were grown from 1.6 M ammonium sulfate in 0.1 M Bis-Tris
(pH 6.5) by the hanging-drop method. These crystals are isomorphous
to the apo Lck crystals [40]. Crystals of apo Lck were obtained under
the same conditions as described above by microseeding the apo
protein sample with the crystals of Lck–AMP-PNP. These crystals were
subsequently soaked for three days in a solution containing 1.6 M
ammonium sulfate, 0.1 M Bis-Tris (pH 6.5) and 0.3 mM staurosporine.
Cocrystals of the Lck–staurosporine complex were grown from 0.1 M
Tris (pH 8.5), 0.25 M Li2SO4, 20% polyethylene glycol (PEG) 6000 by
the hanging-drop method. Diffraction-quality crystals were obtained
after one round of macroseeding. The crystals belong to space group
P212121 with unit-cell dimensions 61.5 × 69.0 × 73.7 Å3 and contain
one complex per asymmetric unit.
Crystals of Lck–AMP-PNP and Lck–staurosporine (soaked) were equili-
brated against a solution containing 1.6 M ammonium sulfate, 0.1 M
Bis-Tris and 20% ethylene glycol and frozen at 100K for data collec-
tion. Diffraction data for the crystals of Lck–AMP-PNP were collected at
the X4A beamline at Brookhaven National Laboratory using an Raxis-IV
image-plate detector. Diffraction data for the Lck–PP2 and Lck–stau-
rosporine cocrystals were collected on an Raxis-II image-plate detector
mounted on the RU300 generator. Lck–PP2 crystals were equilibrated
as above prior to freezing, whereas the Lck–staurosporine cocrystals
were transferred to a solution containing 0.05 M Tris (pH 8.5), 0.025 M
Li2SO4, 20% PEG 6000 and 15% PEG 400 prior to freezing. All data
were processed using the HKL software package [59].
The structure of the Lck–staurosporine cocrystallization complex was
solved by molecular replacement using the program AmoRe [60]. The
apo Lck structure was used as a search model. The initial molecular
replacement solution was subject to rigid-body and positional refine-
ment using X-PLOR [59] (Molecular Simulations, Inc.)
Bound ligands were identified using the difference Fourier method
phased by the structure of apo Lck [40]. Model building of the protein
and inhibitor into electron-density maps was performed using the
graphic program Quanta (Molecular Simulations, Inc.) and the struc-
tures were refined using X-PLOR [61]. The graphic figures were made
using the programs GRASP [62] and SETOR [63]. A summary of the
diffraction data and refinement statistics are given in Table 1.
Kinase activity assays
Protein kinase activity was measured in two different in vitro assays. In
the first assay, the kinase of interest was incubated with [33P]-ATP in a
96-well plate previously coated with substrate (i.e. poly-Glu-Tyr 4:1) and
the kinase activity determined in a Microbeta, Wallac Top-Count
(Packard Instruments). In the second assay, protein kinase autophos-
phorylation was examined. GST-fused Lck proteins consisting of either
the kinase domain (residues 225–509) or nearly full-length sequences
(residues 66–509) were incubated in 10 mM Mg2+, 25 mM Tris 7.5,
1 mM DTT, 1 µM ATP (10 µCi/ml [33P]-ATP) for 5 min at room tempera-
ture with the indicated concentration of compounds. The reaction was
stopped by the addition of one volume of 10% trichloroacetic acid
(TCA) and filtered through a millipore filter plate. After three washes with
200 µl 10% TCA, 50 µl of scintillation cocktail was added to each well
and the plate was read in a microbeta scintillation counter (Wallach).
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T-cell activation
Whole blood was obtained from normal donors and human peripheral
blood lymphocytes (hPBL) were isolated by ficol-hypaque density cen-
trifugation. T cells were then purified from the hPBL by negative selec-
tion using an R&D column following the manufacturers directions (R&D
Systems, Minneapolis, MN). A 96-well flat-bottomed plate was coated
with 10 µg/ml of goat antimouse (GAM) IgG1 (Caltag, Burlingame, CA)
in phosphate buffered saline (PBS) overnight at 4°C. The GAM-coated
plate was flicked out and anti-CD3 mAb (UCHT-1, Coulter/Immunotech,
Miami, FL) added at a concentration of 0.2 µg/ml in AIMV medium
(Gibco, Grand Island, NY) for 3 h at 37°C. Purified T cells were pre-
incubated at 1 × 105/well in AIMV with or without compound for 30 min
then transferred to the anti-CD3 capture plate. Finally, anti-CD28
(Pharmingen, San Diego, CA) in AIMV (150 ng/ml final concentration)
was added to each well. Cells were incubated for 20 h at 37°C in 5%
CO2 then supernatants were tested by enzyme-linked immunosorbant
(ELISA) for cytokine levels (Endogen, Woburn, MA). 
Phosphotyrosine western blotting
Jurkat (ATCC, Manassas, VA) cells (1 × 107) in RPMI-1640 (Gibco,
Grand Island, NY) containing 10% fetal calf serum (FCS) (Sigma, St
Louis, MO) were incubated with or without anti-CD3 mAb (UCHT-1,
10 µg/ml) for 15 min on ice. Cells were washed in cold PBS then incu-
bated with or without GAM IgG1 (10 µg/ml) in RPMI-1640 containing
10% FCS for 15 min on ice. Cells were transferred to a 37°C water
bath for 1 min. Stimulation was stopped by the addition of five volumes
of cold PBS containing 200 µM sodium orthovanadate. Cells were
spun down and lysed in 150 mM Tris/10 mM HEPES buffer (pH 7.3),
containing 1% Triton X-100 and complete protease inhibitor cocktail
(Boehringer Mannheim, Germany) for 30 min on ice. Whole cell lysates
(2 × 106/cell equivalents per lane) were separated by 14% reducing
SDS-PAGE and transferred to PVDF membrane. Blots were probed
with antiphosphotyrosine (4G10, Upstate Biotechnology, Inc., Saranac
Lake, NY) and developed using ECL-plus following the manufacturers
directions (Amersham, Arlington Heights, IL).
Accession numbers
The coordinates will be deposited in the Protein Data bank.
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